Hadasit Bio also announced that it is extending a NIS 1.2 million convertible loan to Biomarker to complete its previous clinical trial, to identify and monitor breast cancer through blood tests, and to fund this latest colon cancer testing trial.
Biomarker develops molecular diagnostic tools based on innovative biomarkers to detect early stage cancer through routine blood tests. Hadasit hold 87.5% of Biomarker.
Hadasit's Bio's share price rose 1.13% in afternoon trading to NIS 0.98.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments